Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5. Beixiange Street, Xuanwu, Beijing, P.R. China.
Am J Chin Med. 2011;39(2):301-13. doi: 10.1142/S0192415X1100883X.
In this study, we investigated the effects of a Chinese herbal medicine formula xiao-gao-jiang-zhuo (XGJZ) in obese rats induced by a high-fat diet. Ten male rats in the normal group were fed with a standard diet. Another 50 male obese rats were induced by a 12-week high-fat diet feeding, and were randomly divided into five groups (n = 10 per group): the model group, the high-dose XGJZ group, the middle-dose XGJZ group, the low-dose XGJZ group, and the sibutramine group. After 14 weeks of treatment, body weight, abdominal fat, blood lipid and serum insulin level were measured, and the protein and gene expression of PTP1B in liver tissue was tested. Our data showed that the body weight of the high-dose and middle-dose groups and the sibutramine group had significant differences in comparison with the model group (p < 0.05), and all three dose groups had significantly reduced abdominal fat (p < 0.05). The triglyceride level of the three dose groups and the sibutramine group, and the total cholesterol level of the middle-dose group were all significantly reduced (p < 0.05). The serum insulin of the high-dose and middle-dose groups also decreased significantly (p < 0.05). The expression of hepatic PTP1B mRNA of the three dose groups decreased significantly in comparison with the model group (p < 0.05 or 0.01). The expression of hepatic PTP1B protein of the high-dose and middle-dose groups decreased significantly (p < 0.05). Our data suggested that XGJZ can modulate the body weight, abdominal fat and blood lipid in the obese rats, and this modulation might improve insulin resistance by inhibiting the PTP1B signal pathway.
在这项研究中,我们研究了中药配方消高降脂(XGJZ)对高脂肪饮食诱导的肥胖大鼠的影响。正常组的 10 只雄性大鼠给予标准饮食。另外 50 只雄性肥胖大鼠给予 12 周高脂肪饮食诱导,并随机分为五组(n = 10 只/组):模型组、XGJZ 高剂量组、XGJZ 中剂量组、XGJZ 低剂量组和西布曲明组。治疗 14 周后,测量体重、腹部脂肪、血脂和血清胰岛素水平,并检测肝组织 PTP1B 蛋白和基因表达。我们的数据显示,与模型组相比,高剂量组和中剂量组以及西布曲明组的体重均有显著差异(p < 0.05),且所有三组的腹部脂肪均显著减少(p < 0.05)。三组和西布曲明组的甘油三酯水平以及中剂量组的总胆固醇水平均显著降低(p < 0.05)。高剂量组和中剂量组的血清胰岛素也显著降低(p < 0.05)。与模型组相比,三组的肝 PTP1B mRNA 表达显著降低(p < 0.05 或 0.01)。高剂量组和中剂量组的肝 PTP1B 蛋白表达显著降低(p < 0.05)。我们的数据表明,XGJZ 可调节肥胖大鼠的体重、腹部脂肪和血脂,这种调节可能通过抑制 PTP1B 信号通路改善胰岛素抵抗。